Bringing innovative medicines to cancer patients around the world

As a biopharmaceutical company, CanWell Pharma Inc. is committed to accelerating the development and commercialization of first-in-class oncology products for targeted cancers to address highly unmet medical needs.

Founded in 2018, CanWell Pharma is led by several highly accomplished veterans who have an average of 25 years of experience in drug discovery and development in both U.S. and China biopharmaceutical industries. CanWell is dedicated to developing its proprietary first-in-class and best-in-class oncology products to address difficult-to-treat advanced cancers. CanWell is developing a rich R&D pipeline with 9 drug candidates under 3 technology platforms.

Our Mission

Our mission at CanWell is to develop innovative treatments that harness the power of the immune system to fight cancer. We are devoted to leveraging the latest advances in immuno-oncology to further explore and develop a variety of innovative therapies. With a focus on collaboration, innovation and patient-centered care, we strive to be at the forefront of cancer immunotherapy and bring new hope to patients and their families.

Immunotherapy platform with two clinical-ready drug candidates, CAN1012 (TLR7 agonist) and DPV-001 cancer vaccine
Read more
Small Molecule Drug Conjugate
Small Molecule Drug Conjugate (SMDC) platform with one clinical drug candidate CAN2109 (ICD inducer) and multiple pre-clinical candidates
Read more
Antibody Drug Conjugate
ADC program includes StarLinker platform powered high DAR ADCs and multiple-agent ADCs, as well as immune-stimulating drug conjugates using TLR agonists as payloads
Read more

Latest News


CanWell Pharma’s First-in-Class innovative drug CAN2109 granted IND approval by China National Medical Products Administration (NMPA)

CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted IND approval by the China National Medical Products Administration (NMPA).  CanWell plans to immediately initiate the patient enrollment…

Read more

CanWell’s CAN2109 IND Granted Approval by US FDA

CanWell Pharma announced that its First-in-Class innovative drug CAN2109, has been granted clinical approval by the US Food and Drug Administration (FDA) and it will soon conduct Phase I clinical…

Read more

Canwell to Present CAN1012 Research Update at the 4th STING & TLR Targeting Therapies Summit

CanWell announced today that the preclinical research results and clinical plan of the company’s TLR7 agonist CAN1012 would be presented at the 4th STING & TLR Targeted Therapy Summit in…

Read more

CanWell was Invited to Present at 9th Immuno-oncology 360° (IO360°) Conference

CanWell presented the preclinical research results of CAN1012, a small molecule TLR7 agonist in the form of an oral presentation at the 9th Immuno-oncology 360° (IO360°) conference. The IO360° conference…

Read more